Ocular Hypertension Completed Phase 4 Trials for Bimatoprost (DB00905)

Also known as: Intraocular pressure raised / Ocular Hypertension (OHT) / Hypertension Ocular / Hypertension, Ocular / Intraocular pressure high / Intraocular hypertension / Ocular Hypertension (OH) / Elevated intraoccular pressure / Intraocular pressure increased / IOP increased / Raised IOP / Ocular tension increased / Tension ocular increased / Pressure intraocular increased / Increased intraocular pressure

IndicationStatusPhase
DBCOND0074237 (Ocular Hypertension)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02061683A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular HypertensionTreatment
NCT02419508SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)Treatment
NCT01298700Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionTreatment
NCT02097719Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionTreatment
NCT00539526Evaluation of Hyperemia With the Use of Ocular Prostaglandin AnaloguesTreatment
NCT02020512A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular HypertensionTreatment
NCT00941096Intraocular Pressure Reduction With the Bimatoprost/Timolol Fixed CombinationTreatment
NCT00847483Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the USTreatment
NCT01937312Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin AnalogueTreatment
NCT01253902Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular HypertensionTreatment
NCT0127168624-hour IOP-lowering Effect of 0.01% BimatoprostTreatment
NCT01263444Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin TherapyTreatment
NCT01464424Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)Treatment
NCT01664039An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®Treatment
NCT0165575824-hour Control of Intraocular Pressure (IOP) in Ocular HypertensionTreatment
NCT01594970A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)Treatment
NCT01547598Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) ReductionTreatment
NCT01525173A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular HypertensionTreatment
NCT01814761A Study of Bimatoprost 0.01% in the Clinical Setting
NCT01833741A Study of LUMIGAN® RC in the Clinical SettingTreatment
NCT01881126An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionTreatment
NCT01170884Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®Treatment
NCT00440011Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%Treatment